OBJECTIVES: Brazil is experiencing an escalation of dengue epidemic activity. After having proven its efficacy, the Sanofi Pasteur dengue vaccine has been recently licensed in Brazil. This evaluation aims to define the economic value of this vaccine in Brazil by estimating the cost-effectiveness price threshold per dose. METHODS: Economic parameters were considered in addition to the public health impact of dengue vaccination, estimated previously through a dengue dynamic transmission model. The analysis was run on 2 vaccination strategies, including a routine at 9 years old and a catch up campaign of 7 cohorts (10 to 16 years old) and 16 cohorts (10 to 25 years old). Brazilian specific demographic, epidemiologic and economic data were used. The economic impact has been assessed over 10-year, from public payer and societal perspectives. All costs were expressed in BRL2013. RESULTS: Over 10 years, the model predicted that dengue vaccination with 7 catch up cohorts campaign would prevent 208,192 [95%CI: 93,949; 336,548] DALYs and save BRL1.17B [95%CI: 0.53B; 1.89B] and BRL4.04B [95%CI: 1.37B; 4.89B] in dengue treatment costs from the public payer and societal perspectives respectively. The cost-effective vaccine price threshold per dose would be BRL168.4 (US$ 74.2) and BRL197.1 (US$ 86.8) respectively. A program with 16 catch up cohorts campaign would prevent 327,580 [95%CI: 130,351; 553,879] DALYs and save BRL1.84B [95%CI: 0.73B; 3.11B] and BRL6.35B [95%CI: 1.90B; 8.07B] in dengue treatment costs from the public payer perspective and societal respectively. The cost-effective vaccine price per dose threshold would be BRL164.05 (US$ 72.3) and BRL191.9 (US$ 84.5) respectively. CONCLUSIONS: The high vaccine price thresholds per dose demonstrate the significant economic value of dengue vaccination in Brazil, even for a large program with 16 cohorts campaign. According to WHO guidelines, dengue vaccination will be cost-effective in Brazil if dengue vaccine is priced below the above thresholds.